Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
Zawartość zarchiwizowana w dniu 2024-06-25
Prevention, diagnosis and molecular characterisation of mismatch repair defect-related hereditary cancers of the digestive system

Article Category

Article available in the following languages:

Understanding the link between DNA repair and cancer

A European consortium advanced knowledge related to the molecular basis of DNA mismatch repair defects and their association to cancer. Project outcomes included the discovery of new genes and new screening methods.

By the term DNA mismatch repair (MMR) scientists refer to the well-conserved process of error correction during replication of the genetic material. A defect in this system can cause certain sections of DNA that contain repeats of a particular sequence – known as microsatellites – to become unstable. This microsatellite instability (MSI) in turn causes cancer. Research has already linked hereditary non-polyposis colorectal cancer (HNPCC) and familial gastric cancer (FGC) with MMR mutations. However, further investigation is required to improve genetic screening and determine the pathogenicity of certain mutations. The main objective of the EU-funded 'Prevention, detection and molecular characterisation of mismatch repair-related hereditary cancers of the digestive system' (MMR-Related Cancer) was to investigate the molecular and genetic background of diseases linked to MMR defects. By linking genotype to patient information, project partners identified new types of mutations on already known MMR susceptible genes. Additionally, they discovered new genes that are affected by MSI and the role of genes whose pathogenicity was unknown. Mutation profiles of MMR cancers were also set up, providing a better insight into tumour development. The MMR-Related Cancer project successfully managed to develop screening methods for early detection of HNPCC and FGC. The identification of new genes combined with the use of mutation-phenotype profiles will improve disease prognosis and treatment. Overall, the study served as another example of the potential of genetic screening as a preventive tool.

Znajdź inne artykuły w tej samej dziedzinie zastosowania

Moja broszura 0 0